The risk of hypoglycemia is increased when WEGOVY is used in combination with insulin or insulin secretagogues (e.g., sulfonylureas)
This allowed us to hypothesize that semaglutide, which works through stimulation of insulin secretion from the beta cell, could potentially replace mealtime insulin administration. From the outset, the goal of the current study was to see if semaglutide treatment could be used to replace mealtime insulin, thereby reducing the insulin dosage, improving glycemic control, reducing the HbA1c and eliminating potentially dangerous swings in blood sugar and hypoglycemia
Keeping everything in your carry-on, clearly labeled
serving as site principal investigator for the current clinical trial, which was sponsored by his university during the conduct of the study
We wrote this paper to kind of say, Hey, lets think about these things before we just started prescribing these medications for kids, Cooper said